These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 22108651)

  • 21. Direct evidence for the up-regulation of spinal micro-opioid receptor function after repeated stimulation of kappa-opioid receptors in the mouse.
    Narita M; Khotib J; Mizoguchi H; Suzuki M; Ozaki S; Yajima Y; Tseng LF; Suzuki T
    Eur J Neurosci; 2003 Nov; 18(9):2498-504. PubMed ID: 14622150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
    Smith PA; Selley DE; Sim-Selley LJ; Welch SP
    Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of kappa opioid receptors in the inhibition of receptor desensitization and PKC activation induced by repeated morphine treatment.
    Hamabe W; Yamane H; Harada S; Tokuyama S
    J Pharm Pharmacol; 2008 Sep; 60(9):1183-8. PubMed ID: 18718122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical anti-opioid action of NPFF2 receptors in rat spinal cord.
    Gouardères C; Zajac JM
    Neurosci Res; 2007 May; 58(1):91-4. PubMed ID: 17337079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.
    Maher CE; Martin TJ; Childers SR
    Life Sci; 2005 Jul; 77(10):1140-54. PubMed ID: 15890372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G protein activation by endomorphins in the mouse periaqueductal gray matter.
    Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
    J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
    Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic treatment with the opioid antagonist naltrexone favours the coupling of spinal cord μ-opioid receptors to Gαz protein subunits.
    Valdizán EM; Díaz A; Pilar-Cuéllar F; Lantero A; Mostany R; Villar AV; Laorden ML; Hurlé MA
    Neuropharmacology; 2012 Feb; 62(2):757-64. PubMed ID: 21903117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.
    Cichewicz DL; Cox ML; Welch SP; Selley DE; Sim-Selley LJ
    Eur J Pharmacol; 2004 Nov; 504(1-2):33-8. PubMed ID: 15507218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mu opioid receptor efficacy and potency of morphine-6-glucuronide in neonatal guinea pig brainstem membranes: comparison with transfected CHO cells.
    Gray RE; Munks MW; Haynes RR; Olsen GD
    Brain Res Bull; 2001 Mar; 54(5):499-505. PubMed ID: 11397539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
    Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a mu-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice.
    Ohsawa M; Mizoguchi H; Narita M; Kamei J; Nagase H; Tseng LF
    Eur J Pharmacol; 2000 Jul; 401(1):55-8. PubMed ID: 10915837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN; Walker EA
    J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
    Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
    Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
    Xie H; Woods JH; Traynor JR; Ko MC
    Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.